Origen Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 5 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.60 M
- Revenue Growth 42.20%
- Profit Growth 38.37%
- Ebitda 47.03%
- Net Worth 146.71%
- Total Assets 24.39%
About Origen Life Sciences
Origen Life Sciences Private Limited (OLSPL) is a Private Limited Indian Non-Government Company incorporated in India on 23 August 2019 (Five years and six months 4 days old ). Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.60 M.
Brahmam Yerroju and Swapna Bikkanuri serve as directors at the Company.
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24230TG2019PTC134988
- Company No.
134988
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Aug 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Origen Life Sciences?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Brahmam Yerroju  | Director | 23-Aug-2019 | Current |
| Swapna Bikkanuri | Director | 23-Aug-2019 | Current |
Financial Performance of Origen Life Sciences.
Origen Life Sciences Private Limited, for the financial year ended 2024, experienced significant growth in revenue, with a 42.2% increase. The company also saw a substantial improvement in profitability, with a 38.37% increase in profit. The company's net worth Soared by an impressive increase of 146.71%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Origen Life Sciences?
Unlock access to Origen Life Sciences's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹1.60 M
₹0
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 0.16 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 Jan 2024 | Hdfc Bank Limited | ₹1.60 M | Open |
How Many Employees Work at Origen Life Sciences?
Unlock and access historical data on people associated with Origen Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Origen Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Origen Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.